Church & Dwight First Response DOT Fails “First And Only” Test – NAD
This article was originally published in The Tan Sheet
Executive Summary
Church & Dwight argues that Swiss Precision Diagnostics should have turned over proprietary information to determine whether its Clearblue product also predicts ovulation based on luteinizing hormone levels because the firm challenged the “only” claim without disputing that First Response works as advertised.
You may also be interested in...
People In Brief
Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.